Voyager Therapeutics (VYGR) Cash & Current Investments (2014 - 2026)

Voyager Therapeutics has disclosed Cash & Current Investments across 13 years of filings, most recently posting $141.5 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $141.5 million, down 40.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $141.5 million (down 40.06% YoY), and the FY2025 annual result was $196.4 million, down 26.34% from the prior year.
• Cash & Current Investments came in at $141.5 million for Q1 2026 at Voyager Therapeutics, down from $196.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $399.6 million in Q1 2024 to a low of $118.8 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $230.9 million (2023), against an average of $233.9 million.
• Across the five-year window, Cash & Current Investments jumped 94.26% in 2023 and tumbled 41.89% in 2025, its largest moves.
• Voyager Therapeutics' Cash & Current Investments stood at $118.8 million in 2022, then surged by 94.26% to $230.9 million in 2023, then climbed by 15.51% to $266.7 million in 2024, then declined by 26.34% to $196.4 million in 2025, then retreated by 27.98% to $141.5 million in 2026.
• The last three Cash & Current Investments figures came in at $141.5 million (Q1 2026), $196.4 million (Q4 2025), and $208.9 million (Q3 2025), per Business Quant data.